Results 51 to 60 of about 26,095 (135)

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi   +6 more
wiley   +1 more source

The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition

open access: yesInternational Journal of Cancer, EarlyView.
Although immune checkpoint inhibitors (ICI) have transformed metastatic melanoma treatment, thromboembolic events (TEEs) remain a serious complication. Moreover, existing risk assessment models were developed prior to ICI use and lack clinical validation.
Tim Zell   +12 more
wiley   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

open access: yesTH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim   +7 more
doaj   +1 more source

Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
A novel one‐step lupus anticoagulant (LA) assay based on the LA‐sensitivity ratio (LA‐SR) was developed to simplify diagnostic testing and reduce potential interference from anticoagulants. The LA‐SR method showed good agreement with guideline‐based LA testing (dRVVT and/or LA‐sensitive APTT) for the detection of LA and demonstrated limited influence ...
Ayu Hidaka   +4 more
wiley   +1 more source

Incidence, contributing factors, and predictors of diagnostic errors in medical inpatients: A retrospective cohort study

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Background Diagnostic error is a major patient safety concern in hospitals, yet most studies have focused on selected high‐risk subgroups, leaving the broader general internal medicine inpatient population understudied. Objectives To determine the incidence, contributing factors, resulting harm, and predictors of diagnostic error in medical ...
Caterina E. Marx   +9 more
wiley   +1 more source

Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients

open access: yesClinical and Applied Thrombosis/Hemostasis
Rivaroxaban was FDA-approved in 2019 for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients. Little to no published data is available to determine the level of correlation between rivaroxaban drug concentration and UFH/LMWH ...
Kaitlin Blotske PharmD   +7 more
doaj   +1 more source

Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives While tranexamic acid (TXA) reduces blood loss in orthopedic surgery, thromboembolic concerns in cancer patients have limited adoption in orthopedic oncology. This study evaluated TXA efficacy and safety in patients undergoing endoprosthetic reconstruction for oncologic indications.
Stephen W. Chenard   +10 more
wiley   +1 more source

Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran

open access: yesBMC Health Services Research
Background Low-dose aspirin and rivaroxaban are the cornerstone treatment for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD).
Zahra Goudarzi   +5 more
doaj   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo   +5 more
wiley   +1 more source

Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events

open access: yesPhytotherapy Research, EarlyView.
An overview of the role of natural products (NP) in cardiovascular disease prevention, highlighting key mechanisms of action: including antiplatelet, antithrombotic, anti‐inflammatory, and antioxidant effects. Additionally, it illustrates the integration of diet–drug interactions, nutritional epigenetics, and the role of artificial intelligence in ...
Maria Nektaria Magkoulia   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy